[Disorders of oculopalpebral motility].
Raspiller
A
A
D000890:Anti-Infective Agents / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000927:Anticonvulsants / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D001763:Blepharoptosis / Q000139:chemically induced*; D001764:Blepharospasm / Q000139:chemically induced*; D002317:Cardiovascular Agents / Q000009:adverse effects; D005133:Eye Movements / Q000187:drug effects*; D005141:Eyelid Diseases / Q000139:chemically induced*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D008094:Lithium / Q000009:adverse effects; D009759:Nystagmus, Pathologic / Q000139:chemically induced*; D009886:Ophthalmoplegia / Q000139:chemically induced; D011619:Psychotropic Drugs / Q000009:adverse effects
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D002317:Cardiovascular Agents; D006993:Hypnotics and Sedatives; D011619:Psychotropic Drugs; D008094:Lithium
Les troubles de la motricité oculo-palpébrale.